Gout: on the brink of novel therapeutic options for an ancient disease.
about
Pegloticase for chronic goutSystemic corticosteroids for acute goutDiagnosis and management of goutTherapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinolEpidemiology, risk factors, and lifestyle modifications for gout"Clinical features of women with gout arthritis." A systematic reviewRole of the leucine-rich repeat domain of cryopyrin/NALP3 in monosodium urate crystal-induced inflammation in mice.Diagnosis and management of gout: a rational approachRecent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeuticsGout, not induced by diuretics? A case-control study from primary care.Sex differences in gout epidemiology: evaluation and treatment.Monosodium Urate Crystals Promote Innate Anti-Mycobacterial Immunity and Improve BCG Efficacy as a Vaccine against Tuberculosis.Sex differences in gout characteristics: tailoring care for women and men.Advances in the management of gout and hyperuricaemia.Quality of care for gout in the US needs improvement.Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.Perceptions of disease and health-related quality of life among patients with goutGout. Novel therapies for treatment of gout and hyperuricemia.Pharmacological Basis for Use of Selaginella moellendorffii in Gouty Arthritis: Antihyperuricemic, Anti-Inflammatory, and Xanthine Oxidase Inhibition.Managing your patient with gout: a review of treatment options.Difficult-to-treat gouty arthritis: a disease warranting better management.Rasburicase for the treatment of tumor lysis in hematological malignancies.Drug discovery for hyperuricemia.Physician adherence to ACR gout treatment guidelines: perception versus practice.Lymphocyte α-kinase is a gout-susceptible gene involved in monosodium urate monohydrate-induced inflammatory responses.Clinicopathologic characterization of visceral gout of various internal organs--a study of 2 cases from a venom and toxin research centerContemporary epidemiology of gout and hyperuricemia in community elderly in Beijing.Dietary component p-coumaric acid suppresses monosodium urate crystal-induced inflammation in rats.Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males.Association between Hyperuricemia and Metabolic Syndrome: An Epidemiological Study of a Labor Force Population in Taiwan.Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's diseaseImpact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study.Insulin resistance and metabolic syndrome in primary gout: relation to punched-out erosions.Rates of adherence and persistence with allopurinol therapy among gout patients in Israel.Suppression of NLRP3 inflammasome by oral treatment with sulforaphane alleviates acute gouty inflammation.Arxula adeninivorans xanthine oxidoreductase and its application in the production of food with low purine content.Toll-like receptors: a new target in rheumatoid arthritis?IL-8 -251T/A and IL-12B 1188A/C polymorphisms are associated with gout in a Chinese male population.
P2860
Q24236711-85553304-0FF7-407E-BF63-5CDDD2417BE2Q24243127-1A9BDAF1-1387-4454-A6F9-BF3964A7C286Q24546235-5CB6CFD0-1811-4656-8273-4860188C2190Q24652967-F5AD9A9C-8C90-4BBB-B2ED-E5328EDFD7C9Q28199023-556C9E22-DF1A-49FE-84BA-7AC2D93FB3AAQ33812247-112284B3-AD10-4728-9252-A62E50723CA0Q34090438-A71A614E-DA54-4DB9-810E-454D4D79EB30Q35522716-0DD65944-FD3D-4D6A-9E21-9F818BD9EA0EQ35578918-AC7F9C68-98FF-45A5-B2AE-F015280499C9Q35637489-878840B6-F2CB-4603-8B86-232B55E02BFEQ35637966-09508E24-48F8-474E-AC81-59017150DB59Q35645947-9577D78B-40C2-47DF-88F8-D47C36CC77DEQ36307823-372673D7-CBC3-4503-BB28-03ACD2132A35Q36554146-156F33CD-5847-4EC0-9AC2-3C78AD339CAEQ36749515-AC165C44-401F-4EB7-8A56-5A1034A655BFQ36903272-E48EB076-05BE-4506-BAB5-C0656B549B69Q37294518-A2E129AB-D084-4406-89BE-245F1C8B0C29Q37350841-22980364-B846-4111-9B2A-B97F0FFD1104Q37640148-547E5D3F-BA48-4952-8E3B-C9252452DABEQ37874889-66491CB2-BDDE-40B0-BCDF-90DE4409C2E8Q37910901-002C688F-EA5B-4400-9EED-0992A9744B62Q37978342-FB5E8F8B-18DF-4862-9159-617ECC6D1356Q38089866-459D6BBF-EC13-45A4-A994-00A21CBD881BQ38219493-122FE769-4A12-4096-A3C5-D8261F8BC56EQ39493628-FB747DF2-4A95-435D-92AB-1FB73C260C04Q39700718-70D43C78-6DFA-4932-89E1-06C59AD5B934Q40143299-B9AC0E0E-CEB0-4C95-B3EF-757441339571Q40257025-CCBB1952-2F2F-4AD4-8D6F-10DE9AC0DB34Q41295678-436ABC6C-7FD4-4353-935A-15BAC886E47FQ42180040-08700A8D-26F2-4228-831E-6A6520C0BD0DQ42456542-5936F01A-B0A7-4FB5-9387-067A67DB619BQ44461648-72CF34A8-D45A-4392-939E-61750737BDF7Q46446936-4380F40D-FA6F-445E-BB39-BB8780B3F97CQ46594268-19975E20-F0C5-4744-A2A9-04DDFDED4D60Q48534533-96866571-2404-49A2-85F5-768710B1CF82Q50901928-5DA7810E-A065-490F-A53E-D99395E5D865Q53614685-803B6168-0B87-489F-BC5D-907989A036EBQ54270738-A84B16A3-7C43-4963-A39A-C318F51AB003
P2860
Gout: on the brink of novel therapeutic options for an ancient disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Gout: on the brink of novel therapeutic options for an ancient disease.
@ast
Gout: on the brink of novel therapeutic options for an ancient disease.
@en
type
label
Gout: on the brink of novel therapeutic options for an ancient disease.
@ast
Gout: on the brink of novel therapeutic options for an ancient disease.
@en
prefLabel
Gout: on the brink of novel therapeutic options for an ancient disease.
@ast
Gout: on the brink of novel therapeutic options for an ancient disease.
@en
P2860
P356
P1476
Gout: on the brink of novel therapeutic options for an ancient disease.
@en
P2093
Jeffry D Bieber
Robert A Terkeltaub
P2860
P304
P356
10.1002/ART.20438
P577
2004-08-01T00:00:00Z